Results 41 to 50 of about 2,458 (69)

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. [PDF]

Antimicrob Agents Chemother
Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group.   +14 more
europepmc   +1 more source

Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021. [PDF]

Antibiotics (Basel)
Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF.   +4 more
europepmc   +1 more source

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients. [PDF]

J Antimicrob Chemother
Gatti M, Rinaldi M, Laici C, Ambretti S, Siniscalchi A, Viale P, Pea F.   +6 more
europepmc   +1 more source

Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. [PDF]

Pathog Immun
Hausman BS, Memic S, Cadnum JL, Zink EG, Wilson BM, Donskey CJ.   +5 more
europepmc   +1 more source

Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. [PDF]

Open Forum Infect Dis
Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa FG, Cattelan AM, Oliva A, Saracino A, Bassetti M, Mussini C, Luzzati R, Capone A, Signorini L, Bartoletti M, Sambo M, Sarmati L, Antinori S, Mularoni A, Tascini C, Corona A, Pascale R, Rubino R, Corcione S, Mazzitelli M, Giuliano G, Lovecchio A, Bavaro DF, Meschiari M, Montagnani F, Fabbiani M, De Benedetto I, Antonelli M, Venditti M, Viale P.   +34 more
europepmc   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam

Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source

Colistin, Meropenem-Vaborbactam, Imipenem-Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2. [PDF]

Antibiotics (Basel)
Forstner P, Fuchs L, Luxner J, Grisold A, Steinmetz I, Dichtl K.   +5 more
europepmc   +1 more source

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion. [PDF]

Front Pharmacol
Laffont-Lozes P, Naciri T, Pantel A, Martin A, Pruvot-Occean AS, Haignere V, Loubet P, Sotto A, Larcher R.   +8 more
europepmc   +1 more source

In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales. [PDF]

Infect Drug Resist
Fu Y, Zhu Y, Zhao F, Yao B, Yu Y, Zhang J, Chen Q.   +6 more
europepmc   +1 more source